Groundbreaking research cooperation: The Medi-Globe Group and the IHU in Strasbourg are developing the world's first AI software for detecting pancreatic diseases
The Medi-Globe Group has entered into a groundbreaking research cooperation with the French Institut Hospitalo-Universitaire (IHU) in Strasbourg. The goal of the collaboration is the world's first AI software for detecting diseases of the pancreas in endoscopic ultrasound examinations. As industrial partner of the IHU, the Medi-Globe Group is thus further expanding its role as an innovation leader in minimally invasive diagnostics and therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220429005471/en/
Groundbreaking research cooperation completed: The Medi-Globe Group and the IHU Strasbourg are developing the world's first AI software for detecting pancreatic diseases. Marc Jablonowski (5th from left), CTIO at the Medi-Globe Group and Dr. Markus Schönberger (5th from right), Director Business Development at the Medi-Globe Group, and the team and the CEO of IHU, Benoit Gallix (4th from right) are delighted. Copyright: Medi-Globe Group
Medi-Globe Group CEO Martin Lehner: "Together with the researchers at the IHU, we will develop the world's first software for the diagnosis of diseases of the pancreas to market maturity. The key technology here is artificial intelligence.”
“We are delighted to announce this special partnership with Medi-Globe Group. This collaboration is an important step in realizing our goal of being a technology leader in the application of artificial intelligence in the field of early detection of pancreatic diseases. Our vision has been to provide technologies that help physicians achieve the best outcome for their patients,” explains Benoit Gallix, CEO of IHU Strasbourg.
Important milestone in the diagnosis of pancreatic cancer in sight
Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose for physicians. Early detection is crucial for the patient's chance of survival. Today in Europe more than 90 percent of patients with pancreatic cancer die.
"In the future, with the support of artificial intelligence, we will be able to make the experience of the world's leading gastroenterologists available to all physicians. Our successful cooperation with the IHU has the potential to revolutionize the diagnosis of pancreatic diseases", says Marc Jablonowski, Chief Technology & Innovation Officer (CTIO) of the Medi-Globe Group.
About Medi-Globe Group
The Medi-Globe Group is an innovative, fast-growing and internationally oriented medical technology group in the fields of urology, gastroenterology and pneumology. The head office is in Achenmuehle in Bavaria. Around 670 employees work for the Medi-Globe Group in Germany, France, the Czech Republic, China, Brazil, the Netherlands and Austria. Customers include university clinics, specialist clinics, special medical facilities and specialists in gastroenterology, urology and pneumology in around 120 countries worldwide. The managing directors are Martin Lehner (CEO), Christian Klein (COO), Dr. Nikolaus König (CFO) and Marc Jablonowski (CTIO).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220429005471/en/
Contact information
press@medi-globe.de
braun communications
Stefanie Braun
+49 171 2 888 214
sb@brauncommunications.de
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:00:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialise cilta-cel.2 “Patients who have relapsed, or for whom treatment regimens have stopped working after experiencing the three major drug classes, typically face poor survival. Despite recent innovation, new therapeutic approaches are still needed,” said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Haematology,
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 06:30:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
Lenovo Group: Full Year Financial Results 2021/2226.5.2022 06:19:00 CEST | Press release
Lenovo Group (HKSE: 992) (ADR: LNVGY) today announced record fiscal year results for the Group, with historic highs for both profit and revenue. Annual net income reached the US$2 billion mark, up 72% year on year, with revenue growing by US$10 billion for the second year running to over US$71 billion. All main business groups were profitable for the full fiscal year - with strong growth momentum in mobile, infrastructure, and solutions and services businesses. Lenovo successfully overcame macro-environmental challenges and demonstrated both agility and resilience as it navigated industry-wide supply shortages, pandemic disruption, geopolitical uncertainties, and higher inflation to deliver a record year. The digital and intelligent transformation trend continues to accelerate, presenting the Group with strong growth opportunities. More than 50% of companies now have digitalization as part of their corporate strategy, up from just over one third two years ago. The hybrid work model is
Exscientia Business Update for First Quarter 202225.5.2022 22:01:00 CEST | Press release
Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005906/en/ Recent advancements in the Company’s pipeline, collaborations, and operations, as well as financial results for the first quarter 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, May 26 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the Company's precision medicine platform. "We started 2022 by commencing a groundbreaking collaboration with Sanofi to develop a pipeline of AI-designed medicines utilising the breadth of our end-to-end platform of AI-driven capabilities from target prioritisation, to drug engineering and patient selection. At this year's American Association of Cancer Research (AACR) Annual Meeting, we highlighted our advancements in this area, including how AI-enabled drug design can help create drug candidates for challenging targets in oncology. In addition, we sho